# NbN3 > Neuroscience-based nomenclature for psychotropic medications for clinicians. (iPhone/iPad app by European College of Neuropsychopharmacology (ECNP).) - Source: https://appshunter.io/ios/app/nbn3/id927272449 (this page in markdown: same URL + `.md`) - Developer: [European College of Neuropsychopharmacology (ECNP)](https://appshunter.io/developer/687721422) - Category: Medical, Health & Fitness - Price: Free - Rating: 4.10/5 from 7 App Store ratings · 18 written reviews indexed - Age rating: 12+ - Requires: iOS 12.0 · 22 MB - Languages: American English - Released: 2014-10-16 - Data updated: 2026-08-01 - Monetization: free - User reviews in markdown: https://appshunter.io/ios/app/nbn3/id927272449/reviews.md ## What is NbN3? It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients. This practice is confusing. • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature. • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”. • In this second edition 22 new medications were added so NbN includes now 130 medications. This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth. The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.   Therefore this nomenclature is based on: 1. The need to treat now. 2. Updated neuroscience insights. 3. The judgment of the members of the taskforce. Along these lines, we have come up with the following proposal: The Nomenclature: Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action. We also added 4 additional dimensions 4 Additional Dimensions: Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.) Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included  Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve" Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.   As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken. ## Key features - Neuroscience-based nomenclature - Pharmacology and mode of action - Approved indications - Efficacy and side effects - Practical clinical notes - Neurobiology details - Links to IUPHAR ## Recent user reviews (10 of 18) All indexed reviews: https://appshunter.io/ios/app/nbn3/id927272449/reviews.md ### 3/5 — Status *2025-09-10, version 3.9.5* Is this app still active? ### 2/5 — Doesn’t open *2025-09-05* The app is incredible but it’s not working. I can’t open it. ### 1/5 — Doesn’t work anymore *2024-09-17* This app doesn’t open anymore…. ### 1/5 — Wonderful app now dead *2023-10-05, version 3.9.3* This used to be a wonderful app but now no longer works at all and does not appear to have been updated for a long time ### 1/5 — Used to be very useful; non-functional now *2023-06-26, version 3.9* The concept behind this app is very important. The classification of medicines used in Psychiatry requires a paradigm shift. This app was previously exceptionally useful to me. Unfortunately, now it is no longer functional with the latest version of iOS on my iPhone. It either doesn't open at all, or opens and immediately crashes. So it has become inoperable. An upgrade would be incredibly welcome! ### 5/5 — Awesome *2023-06-01, version 3.9* In my opinion the relevance and significance of this app just cannot be overestimated 😍 ### 1/5 — Crashes every time I use it *2023-05-11, version 3.8* Used to be very useful. Now crashes when opened or when I search for a drug. The support link is also broken. ### 1/5 — What a shame! *2023-05-01, version 3.6* A really great idea that sadly seems to be buggy and now abandoned! ### 1/5 — It doesn’t work anymore *2023-02-24* The app stopped working (it freezes at the app’s Home Screen) since the update (v3.5) released February 24, 2023. iPhone XR iOS updated (16.3.1). ### 1/5 — Cannot open in iOS system *2021-11-25, version 3.3* I’m very interesting in this application but after download to use with my iPhone 12, it’s cannot open. ## Frequently asked questions about NbN3 ### What is NbN3? NbN3 is a medical application that provides a neuroscience-based nomenclature for psychotropic medications. It aims to reflect current pharmacological knowledge and assist clinicians in making rational treatment decisions. ### What kind of information does NbN3 offer? NbN3 includes details on pharmacology, mode of action, approved indications, efficacy and side effects, practical clinical notes, and neurobiology. It also provides links to the IUPHAR website for further pharmacology information. ### Who developed NbN3? NbN3 was developed by ECNP Research and Scholarship Stichting (De ECNP Research and Scholarship Foundation), a collaboration involving five international organizations: ECNP, ACNP, AsCNP, CINP, and IUPHAR. ### How many medications are included in NbN3? The second edition of NbN3 includes 130 medications, with 22 new medications added since the previous edition. ### Is NbN3 available on multiple devices? Based on the provided data, NbN3 is supported on iPhone and iPod devices. ### How often is NbN3 updated? NbN3 is an ongoing process, and updates, such as new editions, will be undertaken based on user feedback and new findings. The latest version was updated on February 4, 2024. ### What is the age rating for NbN3? NbN3 has an age rating of 12+, making it suitable for users aged 12 and above. ### Does NbN3 have ads? No, NbN3 does not contain advertisements. The application is free to use and does not feature any ads. ## Version history (last 5 releases) ### 3.9.5 — 2024-02-04 - Bug fixes. ### 3.9.4 — 2023-12-31 - Bug fixes. ### 3.9.3 — 2023-09-27 - Bug fixes. ### 3.9.2 — 2023-09-13 - Bug fixes. ### 3.9.1 — 2023-07-06 - Bug fixes. ## Apps similar to NbN3 | App | Rating | Price | Category | | --- | --- | --- | --- | | [NEI Learn](https://appshunter.io/ios/app/nei-learn/id1258833856) | 2.1 (23) | Free | Medical | | [Maudsley Prescribing Guideline](https://appshunter.io/ios/app/maudsley-prescribing-guideline/id1540714057) | 4.5 (85) | Free | Medical | | [PMHNP-BC Pocket Prep](https://appshunter.io/ios/app/pmhnp-bc-pocket-prep/id1105998421) | 4.8 (2,120) | Free | Medical | | [Lanthier](https://appshunter.io/ios/app/lanthier/id701664895) | 3.8 (5) | Free | Medical | | [iCCS](https://appshunter.io/ios/app/iccs/id932264994) | 3.7 (3) | Free | Medical | | [NEI Prescribe](https://appshunter.io/ios/app/nei-prescribe/id911005926) | 4.0 (36) | Free | Medical | ## More apps by European College of Neuropsychopharmacology (ECNP) - [NbN C&A](https://appshunter.io/ios/app/nbn-c-and-a/id1174312826) - [NbN P&F](https://appshunter.io/ios/app/nbn-p-and-f/id1639078524) - [ECNP 2022](https://appshunter.io/ios/app/ecnp-2022/id1644668687) - [ECNP 2024](https://appshunter.io/ios/app/ecnp-2024/id6593677709) - [ECNP 2025](https://appshunter.io/ios/app/ecnp-2025/id6751795110) All apps by European College of Neuropsychopharmacology (ECNP): https://appshunter.io/developer/687721422 ## Related topics [nbn3](https://appshunter.io/ios/topics/nbn3) · [nbn](https://appshunter.io/ios/topics/nbn) · [nmdp](https://appshunter.io/ios/topics/nmdp) --- *Data collected daily from the US App Store and indexed by [AppsHunter](https://appshunter.io/). User reviews are verbatim App Store reviews. Ratings, prices and chart positions refresh continuously; this snapshot is from 2026-08-01.*